• MOG (35-55), EAE, and PARP7 Signaling

  2026-10-13

  MOG (35-55) is a truncated myelin oligodendrocyte glycoprotein peptide used in experimental autoimmune encephalomyelitis research. A 2025 Cell Reports study links PARP7-mediated regulation of STAT1/STAT2 to type I interferon signaling and reports reduced EAE severity after PARP7 inhibition in mice. These findings are mechanistically informative for neuroinflammation research but do not establish a treatment for multiple sclerosis or show that the cited study used the APExBIO product.

• ECM Remodeling and Mitochondrial Homeostasis

  2026-10-13

  Zhang et al. report that extracellular-matrix remodeling, particularly hyaluronan degradation, is linked to mitochondrial remodeling, TGF-β signaling, mitochondrial stress responses, and enhanced pathogen defense in cellular and animal models ([Cell, 2024](https://doi.org/10.1016/j.cell.2024.05.057)). The findings support an ECM-to-mitochondria communication model, but they do not establish clinical benefit or show that Mdivi-1 was used in the study.

• HOXC9, AKT/mTOR and ESCC Apoptosis

  2026-10-12

  A 2026 study links elevated HOXC9 with esophageal squamous cell carcinoma progression and reduced mitochondria-dependent apoptosis through AKT/mTOR-associated signaling. The findings are mechanistically suggestive but remain preclinical, with important limits on biomarker validation and clinical applicability.

• Masitinib (AB1010): Identity and Evidence Scope

  2026-10-12

  Masitinib (AB1010) is described by APExBIO as a phenylaminothiazole-type tyrosine kinase inhibitor associated primarily with KIT and PDGFRα/β research. The available product information supports a conceptual scope spanning cancer biology, gastrointestinal stromal tumor (GIST) models, mastocytosis research, and mast-cell signaling, but no matched research paper was provided. Accordingly, activity values and clinical statements remain supplier-reported claims rather than independently evaluated evidence here.

• Tobramycin: Evidence, Mechanism, and Research Context

  2026-10-10

  A source-grounded overview of Tobramycin as an aminoglycoside antibiotic, examining its reported mechanism, historical comparative susceptibility evidence, conceptual research uses, evidence strength, and limits on modern interpretation.

• Dimethyloxalylglycine (DMOG): Product Overview

  2026-10-09

  Dimethyloxalylglycine (DMOG), SKU A4506, is a research-use chemical marketed by APExBIO as a cell-permeable PHD inhibitor for conceptual studies of HIF regulation and the hypoxia signaling pathway. No matched paper evidence was available for this overview.

• Sunitinib Resistance: From RTK Blockade to Metabolic Context

  2026-10-09

  Sunitinib resistance in renal cell carcinoma is increasingly understood as more than a failure of receptor tyrosine kinase blockade. This thought-leadership analysis examines how LDHA-driven glycolysis, lactate signaling, and HIF-1α-linked angiogenic adaptation may shape response, while distinguishing promising preclinical evidence from clinically actionable proof.

• Afatinib in Gastric Cancer Assembloid Research

  2026-10-08

  Afatinib, also known as BIBW 2992, is an irreversible ErbB-family kinase inhibitor used in cancer biology research. Patient-derived gastric cancer assembloids show why stromal context can change drug-response interpretation, but the cited 2025 study does not establish Afatinib-specific efficacy.

• GSK126 and EZH2: Evidence, Uses, and Limits

  2026-10-08

  GSK126 is a selective EZH2 inhibitor used as a research probe for PRC2-dependent gene regulation. This overview compares supplier-described pharmacology with findings from a 2022 study showing that Ezh2 can regulate inflammasome activation through a methyltransferase-independent mechanism, clarifying the compound’s research value, evidence boundaries, and translational limitations.

• Dual HER2–VEGFR-2 Targeting in Breast Cancer

  2026-10-07

  A 2026 study examined Lapatinib and Telatinib as a dual tyrosine kinase strategy in triple-negative breast cancer cells, linking treatment exposure with reduced proliferation, invadopodia formation, and two-dimensional tube formation. The findings support further phenotype-first research into HER2/VEGFR-2 pathway interactions, while the evidence remains preclinical and does not yet establish direct target engagement or clinical efficacy.

• Sunitinib in RCC: Angiogenesis, Metabolism and Resistance

  2026-10-07

  A source-grounded overview of Sunitinib as a multi-targeted receptor tyrosine kinase inhibitor, emphasizing renal cell carcinoma, angiogenic signaling, glycolytic resistance, published findings on gingerenone A, evidence strength, and translational limitations.

• Anti Reverse Cap Analog in mRNA Translation

  2026-10-06

  Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, is examined here as a variable in the evidence chain linking synthetic mRNA capping, translation initiation, and therapeutic interpretation. The article connects ARCA chemistry with the targeted mRNA nanoparticle study in ACS Nano while separating product claims from peer-reviewed evidence.

• LG 101506 and the RXR–PD-L1 Evidence Gap

  2026-10-06

  LG 101506 is an RXR modulator that can support mechanistic research spanning nuclear receptor signaling, metabolism regulation, and tumor immunology. This article places the compound beside the RBMS1–PD-L1 findings in triple-negative breast cancer, clarifying what the study demonstrates, what remains hypothetical, and how chemical biology can test the connection.

• Dual HER2–VEGFR-2 Targeting in TNBC

  2026-10-05

  The 2026 reference study examines Lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its main contribution is phenotype-focused evidence linking treatment with reduced invadopodia formation, cell proliferation, and two-dimensional tube formation, while also showing why receptor-specific mechanisms require additional validation.

• FMO3–TMAO Signalling in Aging Adipose Dysfunction

  2026-10-05

  A 2024 Hong Kong Polytechnic University thesis proposes that adipose FMO3 is an important local contributor to TMAO accumulation and age-associated white adipose tissue dysfunction. Its multi-model findings connect adipocyte FMO3 to senescence, inflammation, fibrosis, and metabolic impairment, while also identifying a possible TMAO–ASC–NLRP3 mechanism that requires further validation.

8443 records 4/563 page Previous Next 12345 下5页 Last page